Fusion and the bounty of electricity

(photo: ITER Project gangway assembly)

The promise of hydrogen fusion as a safe, environmentally friendly, and virtually unlimited source of energy has motivated scientists and engineers for decades. For the general public, the pace of fusion research and development may at times appear to be slow. But for those on the inside, who understand both the technological challenges involved and the transformative impact that fusion can bring to human society in terms of the security of the long-term world energy supply, the extended investment is well worth it.

Failure is not an option.

Shopify founder Tobias Lütke is backing General Fusion with an undisclosed capital investment through his Thistledown Capital investment firm, the Canadian fusion technology firm announced January 14.

In an article published the same day by TechCrunch, Jonathan Shieber noted that a separate investments by Jeff Bezos, founder and chief executive of Amazon, first made through his venture capital fund nearly a decade ago, means General Fusion “has the founders of the two biggest e-commerce companies in the Western world on its cap table.”

Here is a look back at the top stories of 2020 from our Research and Applications section in Newswire and Nuclear News magazine. Remember to check back to Newswire soon for more top stories from 2020.

Research and Applications section

• ARDP picks divergent technologies in Natrium, Xe-100: Is nuclear’s future taking shape? The Department of Energy has put two reactor designs—TerraPower’s Natrium and X-energy’s Xe-100—on a fast track to commercialization, each with an initial $80 million in 50-50 cost-shared funds awarded through the Advanced Reactor Demonstration Program. Read more.

The Fusion Energy Science Advisory Committee (FESAC), which is responsible for advising the Department of Energy’s Office of Science, on December 4 published the first public draft of Powering the Future: Fusion and Plasmas, a 10-year vision for fusion energy and plasma science. FESAC was charged with developing a long-range plan in November 2018.

The scope: The report, which is meant to catch the eye of leaders in the DOE, Congress, and the White House, details the needs of the fusion and plasma program identified by a FESAC subcommittee—the DOE Fusion Energy Sciences Advisory Committee for Long Range Planning—with the help of the fusion research community. The yearlong Phase 1 of the Community Planning Process, organized under the auspices of the American Physical Society’s Division of Plasma Physics, gathered input and yielded a strategic plan that is reflected in the FESAC’s draft report.

The United Kingdom’s Department for Business, Energy and Industrial Strategy has asked local governments to submit bids to host the Spherical Tokamak for Energy Production project, or STEP, according to an article published by Bloomberg on December 1.

The STEP plant will be developed by the U.K. Atomic Energy Authority, which says that construction could begin as soon as 2032, with operations by 2040, and “will prove that fusion is not a far-off dream.”

The Fusion Enterprise-I and -II sessions, held on November 18 as part of the TOFE 2020 embedded topical meeting at the 2020 ANS Virtual Winter Meeting, were chaired by Ales Necas, principal scientist at TAE Technologies, and featured presentations by speakers representing companies in the commercial fusion area.

The Monday session “Advancement in Medical Isotopes Production and Applications” of the 2020 ANS Virtual Winter Meeting was sponsored by the Isotopes & Radiation Division and co-chaired by Lin-Wen Hu of Massachusetts Institute of Technology and James Bowen of Pacific Northwest National Laboratory.

Radioisotopes produced from nuclear reactors and accelerators are widely used for medical diagnostics and cancer therapy. Technetium-99m (decay product of molybdenum-99), for example, is used in more than 80 percent of nuclear medicine diagnostic procedures. The session featured speakers who discussed the advancement and status of domestic production and applications of medical isotopes.

Wisconsin-based SHINE Medical Technologies announced on November 4 that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lu-177 is a therapeutic isotope in demand by clinical trial sponsors because of its potential to treat a range of cancers.

SHINE said that its production process enables the company to produce the high specific activity, non-carrier-added Lu-177 that is required by today’s clinical trials. In the short term, SHINE will produce Lu-177 at Building One of the company’s Janesville campus while a larger facility is being constructed exclusively for the production of the radioisotope. Building One, which was completed in 2018, houses SHINE’s first integrated, full-size production system and is used to train staff and develop operating history with the equipment.

Groundbreaking for the larger facility is expected in November. According to SHINE, the new production facility will be able to scale to support the company’s anticipated Lu-177 demand for the next five years. It will be capable of producing more than 300,000 doses of Lu-177 per year, the company said.

You may have read the abbreviated version of this article in the November 2020 issue of Nuclear News. Now here's the full article—enjoy!

I have enjoyed a long and stimulating career in applied nuclear physics—specifically nuclear reactor physics, nuclear fusion plasma physics, and nuclear fission and fusion reactor design—which has enabled me to know and interact with many of the scientists and engineers who have brought the field of nuclear energy forward over the past half-century. In this time I have had the fortune to interact with and contribute (directly and indirectly) to the education of many of the people who will carry the field forward over the next half-century.

Cutaway of the SPARC engineering design. Image: CFS/MIT-PSFC, CAD rendering by T. Henderson

Seven open-access, peer-reviewed papers on the design of SPARC, Commonwealth Fusion Systems’ (CFS) fusion tokamak, written in collaboration with the Massachusetts Institute of Technology’s Plasma Science and Fusion Center, were published on September 29 in a special edition of the Journal of Plasma Physics.

The papers describe a compact fusion device that will achieve net energy where the plasma generates more fusion power than used to start and sustain the process, which is the requirement for a fusion power plant, according to CFS.

The timeline for this planned device sets it apart from other magnetic confinement fusion tokamaks: Construction is to begin in 2021, with the device coming on line in 2025.

CFS expects the device to achieve a burning plasma—a self-sustaining fusion reaction—and become the world’s first net energy (Q>1) fusion system. The newly released papers reflect more than two years of work by CFS and the Plasma Science and Fusion Center to refine their design. According to CFS, the papers apply the same physics rules and simulations used to design ITER, now under construction in France, and predict, based on results from existing experiments, that SPARC will achieve its goal of Q>2. In fact, the papers describe how, under certain parameters, SPARC could achieve a Q ratio of 10 or more.